Pulmonary Embolism Response Teams: Structuring a Dedicated Provider Response to Improve Outcomes for Patients and Institutions

Brentuximab vedotin (BV) is an antibody drug conjugate targeting the CD30 antigen. It employs a cleavable protease linking to a monomethyl auristatin E (MMAE) cytotoxic payload. It was 2011 when the first U.S. Food and Drug Administration (FDA) approvals occurred in relapsed/refractory Hodgkin lymphoma (HL) and relapsed/refractory CD30+ anaplastic large-cell lymphoma (ALCL). Single-agent response rates exceeded 75 percent in both settings. The next approval arrived in 2015 to be used as a single-agent maintenance strategy in high-risk HL post–autologous stem cell transplantation. In 2017 it was approved for use in relapsed cutaneous T-cell lymphoma and CD30+ mycosis fungoides. Then, in 2018, it was approved for use in frontline HL as part of the AAVD (adcetris, adriamycin, vinblastine, dacarbazine) regimen based on a modest progression-free survival (PFS) benefit when compared to ABVD (adriamycin, bleomycin, vinblastine, dacarbazine). The HL trial leading to approval was called ESCHELON-1.